Kingenic enters GI therapeutics market.

 27th February 2021

Kingenic is commited to deliver advanced therapeutics covering major therapeutic areas. We identify gastrointestinal therapeutic as an important area of treatment. With our entry into GI segment, Kingenic is commited to make maximum impact in coming years.

Peptox-PD  contain the active substances, pantoprazole sodium and domperidone maleate. Pantoprazole sodium is a selective proton-pump inhibitor (PPI), a medicine that reduces the amount of acid produced in your stomach. It is used for treating acid-related diseases of the stomach and intestine.

Pantoprazole sodium is used to treat adults and adolescents, 12 years of age and above, for the following:

  • Reflux oesophagitis, which is an inflammation of your oesophagus (the tube that connects your throat to your stomach) accompanied by the regurgitation of stomach acid.

Pantoprazole sodium is used to treat adults with stomach and duodenal ulcers.

Domperidone belongs to a group of medicines called ‘dopamine antagonists’ having anti emetic properties. It used in adults and in children to treat nausea (feeling sick) and vomiting (being sick).

Kingenic will launch full range of bio-similars in gastrointestinal therapeutic area in 2021.

More Stories
Kingenic introduces QR packaging security

Counterfeiting products cause financial losses for legitimate brands, involve social costs and losses of unpaid tax for governments. Kingenic Lifescience has implemented quick response code system on our latest packaging material to enhance traceability.

Kingenic launches NSAID range in India

Kingenic announces the Indian launch of Kinamol, it is set to enter NSAID market.  NSAIDs represent a critically important class of medications, Kingenic is commited to launch several more product under this class.

Making medicine accessible by expanding our reach.

By expanding our core distribution capabilities, we help healthcare professionals to serve the patients who depend on them.